¡˜_•¶
1985”N
1)ä—YŽO,“n•Ó‹`–¾
@@Å“_«”]”g”­¶•”ˆÊ‚Ì—˜_“IŒŸo|•û–@‚ÆCTŠŒ©‚Æ‚Ì”äŠr|
@—Տ°”]”g27:36-42,1985.
1988”N
1)ä—YŽO,“n•Ó‹`–¾
@@Å“_«”]”gˆÙí‚Ì”­¶Œ¹‚ÌŽOŽŸŒ³‰ðÍ
@ŒŸ¸‚Æ‹Zp16:1171-1175,1988.
1993”N
1)ŒIŒ´³Žq,’†‘ºMŽq,]“¡‚Ó‚¶Žq,–؉ºKŽq,à_ú±’¼F
@@ELSIA¥F300‚É‚æ‚é‘æ2¢‘ãHCVR‘Ì‘ª’è‚ÌŒŸ“¢
@—Տ°ŒŸ¸‹@Ší¥ŽŽ–ò16:969-972,1993.
1994”N
1)]“¡‚Ó‚¶Žq,ŒIŒ´³Žq,’†‘ºMŽq,”’ì“ÖŽq,–؉ºKŽq,à_ú±’¼F
@@BEP-‡V‚É‚æ‚éRRNAR‘Ì‹y‚эRSmR‘Ì‘ª’è‚ÌŒŸ“¢‚ɂ‚¢‚Ä
@—Տ°ŒŸ¸‹@Ší¥ŽŽ–ò17:209-213,1994.
1996”N
1)’†“‡‹v”üŽq,–؉ºKŽq,–î–쏇Žq,’r“cŸ‹`,¡‘ºˆêŽ},ˆä–{—SŽi
@@•Ÿ‰ªŒ§“à‚É‚¨‚¯‚é—Տ°‰»ŠwŒŸ¸’l‚ÌŽ{ÝŠÔ·¥³‚ÌŽŽ‚Ý
@ˆãŠwŒŸ¸45:886-890,1996.
2)ˆÀ‰i“O,–؉ºKŽq,…–{—²Í,“y‹´³Žq,‰L’r—R”üŽq
@@•Ÿ‰ªŒ§“à‚É‚¨‚¯‚é—Տ°‰»ŠwŒŸ¸’l‚ÌŽ{ÝŠÔ·¥³‚ÌŽŽ‚݁|”Z“x‘ª’荀–ڂɂ‚¢‚ā|
@ˆãŠwŒŸ¸45:892-895,1996.
3)’†Œ´–rŽq,”Ñ“cœAŽq,–؉ºKŽq,’†“‡‹v”üŽq,–î–쏇Žq,…–{—²Í,“y‹´³Žq,Œã“¡’ª
@@“úí“à•”QC‚ƘAŒg‚³‚¹‚½’nˆæ¸“xŠÇ—‘̐§‚ÌŒŸ“¢|‘æ2•ñ•Ÿ‰ªŒ§ŒÜ•a‰@‰ï‚É‚æ‚é–Ú•W’l‚¨‚æ‚ъ”͈͐ݒè‚ÌŽŽ‚݁|
@ˆãŠwŒŸ¸45:1106-1110,1996.
4)‹{–{•q_,Î‹´‘åŠC,’†Œ´–rŽq
@@GOTŒ‹‡«–ƉuƒOƒƒuƒŠƒ“‚É‚æ‚錌´GOT‚’l‚ð’悵‚½1—á
@“à‰Èê–åˆãŠwŽ8:408-410,1996.
1997”N
1)“¡ˆäƒtƒTŽq,‹àé˜a”ü,’†“cO,ˆî—tèñˆê
@@‹ãB‘åŠwˆãŠw•”•‘®•a‰@‚É‚¨‚¯‚é•s‹K‘¥R‘Ì—z«—¦‚ÌŽÀÛ|10”NŠÔ‚Ì’²¸|
@“ú–{—AŒŒŠw‰ïŽGŽ43:364-368,1997.
1998”N
1)‘–{“¹Žq,¼‰ªËŽq,“c粃Vƒdƒ‘,ˆäã{”üŽq,‹{Œ´”üŒbŽq,{“c³—m,–؉ºKŽq,à_ú±’¼F
@@Ž©“®ŒŒ‹…Œv”‘•’uCELL-DYN4000‚ÌŒŸ“¢
@—Տ°ŒŸ¸‹@Ší¥ŽŽ–ò21:545-552,1998.
2)“c粃Vƒdƒ‘,•ž•”KŽq,¼‰ªËŽq,“¡£‰ëŽq,’†Œ´–rŽq,”Ñ“cœAŽq,–؉ºKŽq,’Óc”ŽŽq,à_ú±’¼F
@@[•”Ã–¬ŒŒðÇ‚É”xÇð‚𕹔­‚µ‚½ˆêÇ—á‚É‚¨‚¯‚éƒvƒƒeƒCƒ“S‚̈â“`Žq‰ðÍ
@“ú–{—Տ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ23:730-735,1998.
1999”N
1)•ž•”KŽq,“n粋v”üŽq,ˆäã{”üŽq,¼‰ªËŽq,{“c³—m,‰Y“cŽO’‘ã,’†Œ´–rŽq,”Ñ“cœAŽq,–؉ºKŽq,‹à’n‘דT,’Óc”ŽŽq,à_ú±’¼F
@@ŒŒ‰t‹ÃŒÅ‘æX‡UˆöŽqŠˆ«‚̊”͈͂Ƃ»‚̈â“`Žq‘½Œ^‚ɂ‚¢‚Ä
@“ú–{—Տ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ24:643-647,1999.
2)ä—YŽO,‰i–씎”ü,‹S’ˏr–¾,‘¼
@@Œy“xˆÓŽ¯áŠQ‚Ì”]”g
@—Տ°”]”g41:176-181,1999.
3)–L•Ÿ”ü’ÃŽq,’†éƒgƒ‚Žq,’†Œ´–rŽq,”Ñ“cœAŽq,–؉ºKŽq,N“Œ“V
@@ŠO—ˆŠ³ŽÒƒf|ƒ^‚ð—p‚¢‚½‚—îŽÒ”N—î•ÊŠî€”͈͂̐„’è
@—Տ°•a—47:165-169,1999.
4)’†“c–žŠìŽq,’†Œ´–rŽq,”Ñ“cœAŽq,–؉ºKŽq,‚–ö—Áˆê,à_ú±’¼F
@@ƒRƒŠƒ“ƒGƒXƒeƒ‰[ƒ[’ኈ«‚ðŽ¦‚µ‚½ˆêÇ—á‚̈â“`Žq‰ðÍ
@—Տ°‰»Šw28:182-187,1999.
2000”N
1)ä—YŽO,–؉ºKŽq,à_ú±’¼F
@@ƒCƒ“ƒgƒ‰ƒlƒbƒg‚É‚æ‚鐶—ŒŸ¸ƒIƒ“ƒ‰ƒCƒ“ƒVƒXƒeƒ€ @
@“ú–{—Տ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ25:195-200,2000.
2001”N
1)ä—YŽO,Žð“c‚ ‚ä‚Ý,‰i–씎”ü,X‰ª—²l
@@“ª”çã”]”g‚É‚æ‚é“«‘¤“ª—t‚Ä‚ñ‚©‚ñ‚Ì‚Ä‚ñ‚©‚ñŒ´«ˆæ‚̐f’f
@“ú–{—Տ°_Œo¶—Šw‰ï29:366-373,2001.
2)–؉ºKŽq,–L•Ÿ”ü’ÃŽq,”Ñ“cœAŽq,˜eŽRƒ}ƒ`Žq,ŒIŒ´³Žq,’†Œ´–rŽq,“c粃Vƒdƒ‘,à_ú±’¼F,‘¼ •Ÿ‰ªŒ§ŒÜ•a‰@‰ï,•Ÿ‰ªŒ§‹ZŽt‰ï,•Ÿ‰ªŒ§ˆãŽt‰ï
@@•Ÿ‰ªŒ§‚É‚¨‚¯‚é—Տ°ŒŸ¸‘ª’è’l•W€‰»‚ÌŒ»ó
@—Տ°•a—49:512-521,2001.
3)“ì—¯”ü,‰Y“c”ü’‘ã,ŒIŒ´³Žq,Œ´Œhˆê,ˆÀ•”NM,–¼˜a“cV,–´“ckˆê˜Y
@@“–‰È‚ÅŒoŒ±‚µ‚½ƒvƒƒeƒCƒ“SŒ‡–RÇ‚Ì3—á
@—Տ°ŒŒ‰t42:610-615,2001.
4)‘–{“¹Žq,ŽRŒûœAŽq,ˆäã{”üŽq,‰i–씎”ü,“¡£‰ëŽq,“¡ˆä’q”ü,–؉ºKŽq,à_è’¼F,‰v–{N‘ã,“¡–{Œh“ñ
@@XE-2100‚É‚¨‚¯‚郊ƒT[ƒ`€–ÚOtheri“j‚Ì•]‰¿
@ƒVƒXƒƒbƒNƒXƒWƒƒ[ƒiƒ‹23:51-55,2001.
2002”N
1)¬–ì”ü—R‹I,’†‘ºMŽq,–؉ºKŽq
@@ŒÄ‹zŠíŽ¾Š³Š³ŽÒ‚É‚¨‚¯‚錌´KL-6‘ª’è‚Ì—L—p«
@ˆãŠwŒŸ¸51:49-52,2002.
2)•ž•”KŽq,ŽRŒû‹±Žq,‰Y“c”ü’‘ã,–؉ºKŽq,”Ñ“cœAŽq,à_ú±’¼F
@@“ûŽ_’E…‘fy‘fHƒTƒuƒ†ƒjƒbƒg•ÏˆÙ‚Ì1Ç—á-ƒRƒhƒ“230‚É‚¨‚¯‚éƒOƒ‹ƒ^ƒ~ƒ“Ž_‚©‚烊ƒWƒ“‚Ö‚Ì’uŠ·
@—Տ°‰»Šw31:51-57,2002.
3)’†Œ´–rŽq,ŒIŒ´³Žq,–؉ºKŽq
@@ƒOƒŠƒRƒwƒ‚ƒOƒƒrƒ“A1cˆÙíƒpƒ^[ƒ“‚©‚瓾‚ç‚ꂽƒwƒ‚ƒOƒƒrƒ“ˆÙíÇ4—á‚̉ðÍ
@ˆãŠwŒŸ¸51:34-39,2002.
4)›Á“ú³,¼“‡F[,“¡ˆä’q”ü,”’“yŠî–¾,ˆÀ•”NM,¼‘ºƒ“ñ,–¼˜a“cV,–´“ckˆê˜Y
@@Ä”­Žž‚Ép190 type bcr/ablƒLƒƒ‰mRNA‚ð”F‚ß‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a
@—Տ°ŒŒ‰t43:836-840,2002.
2003”N
1)‰Y“c”ü’‘ã
@@ŠÖßƒŠƒ…ƒEƒ}ƒ`‚É‚¨‚¯‚錌´’†ƒ}ƒgƒŠƒbƒNƒXƒƒ^ƒƒvƒƒeƒA[ƒ[-3iMMP-3j‚¨‚æ‚эRƒKƒ‰ƒNƒg[ƒXŒ‡‘¹IgER‘́iCA¥RFj‘ª’莎–ò‚ÌŠî‘b“IŒŸ“¢
@—Տ°•a—51:745-750,2003.
2)¬–ö‚³‚­‘ã,ä—TŽO,Žð“c‚ ‚ä‚Ý,‘O“cƒgƒ‚Žq,–؉ºKŽq,à_ú±’¼F
@@Dlco‚¨‚æ‚ÑDlcof“¯Žž‘ª’è‚Ì”x‹@”\ŒŸ¸ƒXƒNƒŠ[ƒjƒ“ƒOã‚̈Ӌ`|“VC‚Æ‚Ì”äŠr|
@ˆãŠwŒŸ¸52:243-246,2003.
3)]“ª’åb,ŠœX—TŽO,à_ú±’¼F
@@—AŒŒŒŸ¸‚ÌŽ©“®‰»
@—Տ°•a—ƒŒƒrƒ…[“ÁW126:67-71,2003.
4)“¡ˆä’q”ü,ˆäã{”üŽq,h“‡‹Ml,‘–{“¹Žq,ŽRŒûœAŽq,–؉ºKŽq,–´“ckˆê˜Y,à_è’¼F
@@–«œ‘«”’ŒŒ•a‚É”F‚ß‚ç‚ê‚ébcr/ablƒLƒƒ‰ˆâ“`Žq‹y‚ÑWT1ˆâ“`Žq‚Ì’è—Ê“IŒŸo
@—Տ°•a—51(9):839-846,2003.
5)“¡ˆä’q”ü,‘–{“¹Žq,ˆäã{”üŽq,‰Y“c”ü’‘ã,ŒIŒ´³Žq,”Ñ“cœAŽq,–؉ºKŽq,à_ú±’¼F
@@ŒŒ´ALT’ኈ«Ç—á‚É‚¨‚¯‚éˆâ“`Žq‰ðÍ
@—Տ°‰»Šw32:255-259,2003.
6)˜a“cŒ‹,h“‡‹Ml,ˆäãŒb,ì‘º”ü“ÞŽq,ŒIŒ´³Žq,‘–{“¹Žq,–L•Ÿ”ü’ÃŽq,”Ñ“cœAŽq,ŠœX—TŽO,–؉ºKŽq,à_ú±’¼F
@@ŒŒ‰t‹ÃŒÅŒŸ¸¥ŒŒ‹…Œv”¥¶‰»Šw“IŒŸ¸‚̐¶—“I•Ï“®•‚Æ‹–—eŒë·ŒÀŠE‚̐ݒè
@—Տ°‰»Šw32:200-209,2003.
7)‹TŽqŒõ–¾,Â–Ø‹`­
@@Rapid tunover protein ‚̐¶—Šw“I•Ï“®
@“ú–{—Տ°ŒŸ¸Ž©“®‰»Šw‰ïŽ28:647-651,2003.
2004”N
1)X‘å•ã,¡‘º³ˆê,–L•Ÿ”ü’ÃŽq,–؉ºKŽq,ŠœX—TŽO,à_ú±’¼F
@@•a‰@ˆã—Ïî•ñƒVƒXƒeƒ€‚ƘAŒg‚µ‚½POCTƒVƒXƒeƒ€‚̍\’z‚Ɖ^—p
@“ú–{—Տ°ŒŸ¸Ž©“®‰»Šw‰ï29:196-200,2004.
2)ŽRŒû‹±Žq,ŠœX—TŽO,à_è’¼F
@@“úí‹Æ–±‚É‚¨‚¯‚éƒwƒ‚ƒOƒƒrƒ“ˆÙíÇ‚Æ‚»‚̉ðÍƒVƒXƒeƒ€
@“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŽGŽ5:56-63,2004.
3)ˆäã{”üŽq,“¡ˆä’q”ü,–؉ºKŽq,–´“ckˆê˜Y,à_ú±’¼F
@@CML‹}«“]‰»‚ÌŽw•W‚Æ‚µ‚ÄWT1ˆâ“`Žq’è—ÊŒŸ¸‚ª—L—p‚Å‚ ‚Á‚½1Ç—á
@“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŽGŽ5:168-175,2004.
4)Michiyo Urata,Yui Wada,Sang Ho Kim,Worawan Chumpia,Yuzo Kayamori,Naotaka Hamasaki,Dongchon Kang
@@High-Sensitivity Detection of the A3243G Mutation of Mitochondrial DNA by a
Combination of Allele-Specific PCR and Peptide Nucleic Acid-Directed PCR Clamping
@Clinical Chemistry50:11,2045-2051,2004
2005”N
1)¡‘º³ˆê,–L•Ÿ”ü’ÃŽq,–x“c‘½ŒbŽq,•ž•”KŽq,ŒIŒ´³Žq,‘–{“¹Žq,–؉ºKŽq,ŠœX—TŽO,à_ú±’¼F
@@ŒŸ‘ÌŒŸ¸•”–哝‡‰»‚É”º‚¤”À‘—ƒVƒXƒeƒ€‚Ì“±“üŒø‰Ê‚ÆŒø—¦“I‚Ȑf—ÃŽx‰‡
@“ú–{—Տ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ30:66-74,2005.
2)ˆäã{”üŽq,“¡ˆä’q”ü,‰Y“c”ü’‘ã,˜a“cŒ‹,¬–ì”ü—R‹I,ŒIŒ´³Žq,ƒEƒHƒ‰ƒƒ“ƒ`ƒ…ƒ“ƒsƒA,”Ñ“cœAŽq,–؉ºKŽq,’Óc”ŽŽq,N“Œ“V,à_ú±’¼F
@@ƒvƒƒeƒCƒ“SŠˆ«’ቺ‚ðŽ¦‚µ‚½ŒŒðÇŠ³ŽÒ‚ÉŒ©o‚³‚ꂽ•ÏˆÙŒ^ƒvƒƒeƒCƒ“S•ªŽq‚Ì‹@”\‰ðÍ
@“ú–{ŒŒðŽ~ŒŒŠw‰ïŽ16:641-649,2005.
3)¼ˆä—ç,“¿–{³Œ›,“¡è‹Bˆê˜Y,’JŒû³’q,•½ì—º,•½•ûGŽ÷,”Ñ“cŽO—Y,Â–Ø‹`­,à_ú±’¼F
@@”A’`”’ŽŽŒ±Ž†iMultistix PRO 10LSj‚ÆCLINITEK500‚𕹗p‚µ‹‚ß‚½”A’`”’¥”AƒNƒŒƒAƒ`ƒjƒ“”ä   iP/Crj‚Ì—L—p«
@—Տ°‚ÆŒ¤‹†82:4:713-718,2005.
4)Tomoko Ichibangase,Chie Hamabe,Yoshihito Ohba,Naoya Kishikawa,Kenichiro Nakashima,Yuzo Kayamori,Dongchon Kang,Naotaka Hamasaki,Naotaka Kuroda
@@Study on immunocapture-chemiluminescence assay of lipase activity in a biological sample
@Luminescence 21:62-66,2005.
5)ŠœX—TŽO
@@–òŠw¶‚Ì‚½‚߂̗Տ°‰»Šw ‰ü’ù‘æ2”Å;Œã“¡‡ˆê,•ÐŽR‘PÍi•Òj
@“ì]“°;“Œ‹ž,63-74,2005.
2006”N
1){“c³—m,ŠœX—TŽO,–´“c³ˆê,ŒK‰ªŒM,’†“‡Ž},â–{‰xŽq,ˆê£N_,‰¡ˆä_,ˆ¢“쌚ˆê
@ ÔŒŒ‹…Œ`‘Ô‚Ì•W€‰»‚ɂ‚¢‚Ä
@“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŽGŽ7:120-129,2006.
2)Ikunosuke Sakurabayashi,Tatsuo Watano,Nobuo Inaba,Koji Kishi,Kazuaki Yamashita,Yuzo Kayamori
@ Proposal of automation of candidate reference method for the accurate serum
cholesterol assay in clinical laboratories.
@Clinica Chimica Acta 364:246-250,2006
3)Taisuke Kanaji,Kumiko Watanabe,Sachiko Hattori,Michiko Urata,Hiroko Iida,
@Sachiko Kinoshita,Yuzo Kayamori ,Dongchon Kang,Naotaka Hamasaki.
@ Factor ‡]‡Ugene (F12)-4C/C polymorphism in combination with low protein S activity is   associated with deep vein thrombosis.
@Thromb Haemost 96:854-5,2006
4)Masakazu Nakamura,Yuzo Kayamori,Shinichi Sato,Takashi Shimamoto.
@ Lipid Standardization Result of Japanese Manufacturers by US Cholesterole Reference
Method Laboratory Network Certification Protocols and Reagents' Specificity and
Performance. In:Forcus on Cholesterole Research.
(Ed)MA Kramer : 75-146,Nova Science Publishers Inc.,New York . 2006.
5)ŠœX—TŽO,X‰º–FF,¼–{—S”V,‰¬’Ã’¼’Ê,–ØàVåŽŸ,‘O“cŒåŽi,‘“cŽD,‹g“c—²‘¥,“ސ{³l,”~–{‰ë•v,•ÐŽR‘PÍ
@ ŒŒ´’†‚Ì‘ƒRƒŒƒXƒeƒ[ƒ‹”Z“x‘ª’è‚ÌŠ©–@
@—Տ°‰»Šw35:390-419,2006.